Methionine.

Glycine N-methyltransferase uses glycine to absorb surplus methyl groups from SAM, which is the body's main route for handling a methionine load. Glycine supply is what keeps the methylation cycle from backing up.

Betaine-homocysteine methyltransferase transfers a methyl group from betaine to homocysteine, regenerating methionine independently of folate. It is the direct partner reaction to methionine turnover.

Betaine is the substrate BHMT uses to convert homocysteine back into methionine in liver and kidney. That pathway runs in parallel to the folate route.

Choline is oxidised to betaine, which then donates a methyl group to homocysteine. Choline intake therefore feeds methionine regeneration one step upstream.

5-methyltetrahydrofolate is the methyl donor that methionine synthase uses to rebuild methionine from homocysteine. Folate and methionine are two points on one cycle.

Methionine synthase requires methylcobalamin to accept a methyl group from folate and pass it to homocysteine. Without B12 the folate route to methionine cannot turn over.

Folate carries the one-carbon unit that methionine synthase transfers to homocysteine. Folate status shapes how efficiently a methionine load is recycled rather than accumulated.

Cystathionine beta-synthase and cystathionine gamma-lyase both use pyridoxal phosphate to move homocysteine onward into cysteine. B6 is what opens the exit route from the methionine cycle.

MTHFR uses FAD from riboflavin to generate the methylfolate that methionine synthase needs. Riboflavin status sits one step behind the folate arm of the cycle.

Methionine synthase and betaine-homocysteine methyltransferase are both zinc metalloenzymes that use the metal to activate the thiol of homocysteine. Zinc is required for either remethylation route.

Methionine adenosyltransferase converts methionine plus ATP into SAM, the universal methyl donor. The two are consecutive members of the same pathway, so both should not be pushed hard at once.

Cysteine is made from the sulfur of methionine through the transsulfuration pathway, so supplying cysteine spares methionine for methylation instead. This sparing relationship is long-established nutrition biochemistry.

NAC feeds the same cysteine pool that methionine sulfur otherwise supplies, easing the demand on transsulfuration. It also raises homocysteine handling load, so B6 status matters alongside.

Cysteine derived from methionine is the rate-limiting residue of glutathione synthesis, so methionine sits upstream of the body's main thiol. Supplying glutathione directly reduces the pull on methionine sulfur.

Taurine is formed from cysteine, which itself comes from methionine sulfur, so taurine intake spares that route. The three sit on one sulfur pathway.

Endogenous creatine synthesis consumes a large share of the body's SAM methyl groups, so taking creatine lowers that methyl demand and spares methionine. A settled and often overlooked link.

Serine donates its side chain carbon to the folate pool through serine hydroxymethyltransferase, generating the units that remethylate homocysteine. Serine supply feeds methionine regeneration indirectly.

Carnitine synthesis begins with lysine residues trimethylated using SAM, which is derived from methionine. Methionine is the methyl source behind endogenous carnitine.

Carnitine synthesis starts when lysine residues in protein are methylated three times, and every one of those methyl groups comes from S-adenosylmethionine made out of methionine. Lysine supplies the carbon skeleton, methionine supplies the methyl. The two are also the amino acids most often limiting in cereal-based diets, which is why they are supplemented together in production animals. Human data for the pairing as a supplement is not what this row rests on.

Methionine adenosyltransferase joins methionine to ATP to make S-adenosylmethionine, and that reaction runs on a magnesium-ATP complex rather than free ATP. Without magnesium in the active site the transfer does not proceed. This is settled enzymology and needs no trial to state. It says nothing about whether extra magnesium raises methylation in a person with adequate status.

Methionine adenosyltransferase is stimulated by monovalent cations, with potassium the physiological one. The effect is on enzyme kinetics measured in purified systems, not on any clinical endpoint. Ordinary dietary potassium covers this. Read it as mechanistic context for how methionine becomes a methyl donor.

Creatine is built in two steps: arginine and glycine combine to form guanidinoacetate, then guanidinoacetate is methylated using S-adenosylmethionine derived from methionine. Arginine gives the amidino group, methionine gives the methyl. This single reaction accounts for a large share of the body's daily methyl transfer. It is biochemistry, not a claim about supplementing both.

The liver can build phosphatidylcholine by methylating phosphatidylethanolamine three times, and each methyl comes from S-adenosylmethionine. Dietary phosphatidylcholine reduces how much of that route the body needs to run, which lowers methyl-group demand. Methionine supply and choline supply therefore sit on the same ledger. Neither substitutes fully for the other.

The final step of melatonin synthesis methylates N-acetylserotonin, and the methyl group is donated by S-adenosylmethionine made from methionine. That is the biochemical link between the two. It does not mean taking methionine raises melatonin, and supplemental melatonin bypasses the step entirely. The relevance is mechanistic.

A published protocol describes a trial giving branched-chain amino acids alone or with tryptophan or with methionine and measuring appetite-related responses. It is a design paper, so no results support the pairing yet. Separately, tryptophan-derived serotonin is methylated using methionine-derived methyl groups on the way to melatonin. Count this as a planned comparison, not an established combination.

The same protocol places leucine-containing branched-chain amino acids alongside methionine in an appetite-response comparison. No outcome data are reported in a protocol. Both are indispensable amino acids that compete for the same neutral amino acid transporters, which is the mechanistic reason to study them together. Read the pairing as under investigation.

Excess nicotinamide is cleared by nicotinamide N-methyltransferase, which spends a methyl group from S-adenosylmethionine on every molecule it disposes of. Large niacin intakes therefore draw on the same methyl pool methionine feeds. The interaction is a demand on methyl groups, not a change in absorption of either nutrient. It is well described and needs no trial to state.

Nicotinamide disposal runs through the same S-adenosylmethionine-dependent methylation step as niacin, producing methylnicotinamide. The methyl groups ultimately trace back to methionine and the folate cycle. At ordinary intakes this is a background cost; at high intakes it becomes a measurable draw on methyl supply. What follows for a person's methylation markers depends on their folate and B12 status.

Selenomethionine is handled by the body as if it were methionine and gets incorporated non-specifically into protein in its place. How much selenium ends up stored in tissue protein therefore depends on methionine supply: more methionine means more of the selenomethionine is directed toward the selenium-specific routes instead of protein. This is an incorporation relationship, not an effect on any measured outcome. It matters most when selenium is taken as selenomethionine rather than as selenite.

Chromium methionine is a chelated mineral form in which methionine is the ligand carrying the metal. A lactation trial in dairy cattle reported effects of chromium methionine supplementation on production and antioxidant measures. That is animal work with markers, not a human outcome. The relevant point for a formulator is that methionine is functioning as the carrier, not as a separate active.

Copper methionine complexes are used where a chelated mineral is wanted, with the amino acid stabilising the metal against binding to competing dietary ligands. Copper and methionine also co-occur heavily in the sulfur-metabolism literature because thiol-containing metabolites bind copper. The chelate is a delivery choice, and it is described here without any suggestion that one carrier is better than another.

Manganese methionine belongs to the same family of amino acid mineral chelates, with methionine as the ligand. Chelation changes the chemical environment the mineral travels in rather than adding an action of its own. Human comparative data for this specific chelate is thin. Regard it as a formulation option described, not ranked.

Methionine has been used as a ligand in amino acid iron complexes, the same principle behind glycine-chelated iron. Iron also appears alongside methionine in heme and sulfur-metabolism literature because both feed into the same redox environment. Neither point is a human absorption claim. It is context for why the two names appear together.

Folic acid is reduced to tetrahydrofolate and then to 5-methyltetrahydrofolate, which is the methyl donor that lets methionine synthase rebuild methionine from homocysteine. Without folate in that reduced form, the remethylation route stalls and homocysteine accumulates. Folic acid requires the extra reduction step that already-reduced folates do not. That is a chemistry difference, not a ranking.

In brassica plants, methionine is the starting amino acid for the chain-elongation sequence that builds glucoraphanin, the glucosinolate that yields sulforaphane. The link is in the plant, not in human metabolism, which is why it explains sulfur chemistry rather than any combined effect in a person. It is worth naming because both compounds are described as sulfur nutrients and are often assumed to interact in the body. They do not, on this route.